跳至主要内容
临床试验/NL-OMON20599
NL-OMON20599暂停不适用

A randomised controlled trial in HIV positive patients comparing the efficacy of lopinavir/ritonavir monotherapy versus conventional triple therapy.

VU Medical CenterandUniversity Medical Center Utrecht0 个研究点目标入组 240 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
发起方
入组人数
240

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subject is HIV-1-infected;
  • 2. Subject is on a first or second line antiretroviral therapy consisting of either 1 PI or 1 NNRTI and at least 2 NRTI;
  • 3. Subject has a HIV-1 RNA load < 50 copies/ml for at least 3 months;
  • 4. EDTA plasma from before initiation of first or second line antiretroviral therapy is available for genotyping;
  • 5. Subject is at least 18 and not older than 65 years of age;
  • 6. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.

排除标准

  • 1. Any mutation in the protease at codon 32, 46, 47, 48, 50, 54, 82, 84 or 90 or more than 2 mutations in the protease at codon 10, 20, 24, 33, 53, 63, 71, 73;
  • 2. Any Protease Inhibitor regimen failure;
  • 3. Any of the following mutations in the reverse transcriptase: M41L, D67N, K70R, L210W, T215Y or T215F, K219Q, K219E, or K65R;
  • 4. History of sensitivity/idiosyncrasy to lopinavir/ritonavir;
  • 5. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion;
  • 6. Inability to understand the nature and extent of the trial and the procedures required;
  • 7. Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female;
  • 8. HBsAg positive hepatitis B infection;
  • 9. Abnormal serum liver enzymes or creatinine, determined as levels being > 3 times upper limit of normal;
  • 10. Fasting plasma triglyceride level > 3.0 mmol/l (= 265.8 mg/dl) in non-Kaletra containing regimens despite the use of lipid lowering drugs;
  • 11. Fasting plasma total cholesterol level > 6.2 mmol/l (=239.9 mg/dl) in non-Kaletra containing regimens despite the use of lipid lowering drugs;
  • 12. Concomitant use of medications that interfere with lopinavir pharmacokinetics.

研究者

发起方
VU Medical CenterandUniversity Medical Center Utrecht

相似试验

HAART followed by maintenance with... | 临床试验